|
|
|
19.03.26 - 21:06
|
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates (Business Wire)
|
|
|
Advancing two Phase 2 studies evaluating tibulizumab in hidradenitis suppurativa (HS) and systemic sclerosis (SSc)
Topline data expected from the Phase 2 TibuSHIELD study in HS in the fourth quarter of 2026 and from the Phase 2 TibuSURE study in SSc in the first half of 2027
Cash and cash equivalents of $109.4 million as of December 31, 2025
Completed an underwritten public offering in February 2026 for gross proceeds of approximately $144 million; post‑financing cash and cash equivalents expected to support planned operations through at least the end of 2028
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical‑stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today reported financial results for the full year ended December 31, 2025, and provided recent corporate updates.
“2025 was a year of strong execution ...
|
|
|
|
|
27.02.26 - 12:36
|
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters′ Option to Purchase Additional Shares (Business Wire)
|
|
|
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it closed its previously announced underwritten public offering of Class A ordinary shares and pre‑funded warrants on February 26, 2026.
The offering consisted of 21,200,000 Class A ordinary shares priced at $6.25 per share, along with pre‑funded warrants for 1,800,000 Class A ordinary shares priced at $6.249 per warrant, which included 3,000,000 additional Class A ordinary shares sold upon exercise in full by the underwriters of their option to purchase additional shares of stock in the offering. All shares and pre-funded warrants were sold by Zura.
Gross proceeds from the offering were approximately $144 million, before deducting underwriting discounts and commissions and other offering e...
|
|
|
|
|
25.02.26 - 12:36
|
Zura Bio Announces Pricing of $125 Million Public Offering of Class A Ordinary Shares and Pre-Funded Warrants (Business Wire)
|
|
|
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the pricing of its previously announced underwritten public offering of 18,200,000 Class A ordinary shares at a price to the public of $6.25 per share and, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase 1,800,000 Class A ordinary shares at a price to the public of $6.249 per pre-funded warrant, which equals the public offering price per Class A ordinary share, less the $0.001 exercise price of each pre-funded warrant. In addition, Zura has granted the underwriters a 30-day option to purchase up to an additional 3,000,000 Class A ordinary shares at the public offering price, less underwriting discounts and commissions. All of the Class A ordinary shares and...
|
|
|
24.02.26 - 22:03
|
Zura Bio Announces Proposed Public Offering of Class A Ordinary Shares and Pre-Funded Warrants (Business Wire)
|
|
|
HENDERSON, Nev.--(BUSINESS WIRE)--Zura Bio Limited (Nasdaq: ZURA), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced that it has commenced an underwritten public offering of its Class A ordinary shares or, in lieu of Class A ordinary shares to certain investors that so choose, pre-funded warrants to purchase Class A ordinary shares. In addition, Zura expects to grant the underwriters a 30-day option to purchase additional Class A ordinary shares in an amount of up to 15% of the aggregate number of shares and shares underlying the pre-funded warrants sold in the offering at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the propo...
|
|
|
23.02.26 - 12:31
|
Zura Bio Welcomes Accomplished Drug Development Leaders Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to Board of Directors (Business Wire)
|
|
|
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura” or the “Company”), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today announced the appointments of Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors, effective February 21, 2026. As part of this transition, Neil Graham, M.B.B.S., M.D., M.P.H., will step down from the Board effective the same date.
“Mark and Ajay are accomplished immunology executives who have successfully guided innovative biologics from early development through approval and commercialization on a global scale,” said Amit Munshi, Chairman of the Board. “As we advance our Phase 2 programs and evaluate new growth opportunities, their experience will be instrumental. Their decision to join the Board reflects their conviction in our strategy and pipeline...
|
|
|
|
|
|
|
|
|
13.11.25 - 12:33
|
Zura Bio Reports Third Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire)
|
|
|
Continued advancement of two Phase 2 clinical trials evaluating tibulizumab in hidradenitis suppurativa (HS) (TibuSHIELD) and systemic sclerosis (SSc) (TibuSURE), with topline data expected in the second half of 2026.
Reported $139.0 million in cash and cash equivalents as of September 30, 2025, which is expected to fund planned operations through 2027.
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported financial results for the third quarter ended September 30, 2025, and provided recent corporate and pipeline updates.
“Both tibulizumab studies advanced during the quarter,” said Kiran Nistala, MBBS, PhD, Chief Medical Officer and Head of Development at Zura Bio. “We continue to focus on disciplined study execution and patient enrollment across these important disease areas, with the ai...
|
|
|
|
|
|
|
|
|
14.08.25 - 14:21
|
Zura Bio Reports Second Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire)
|
|
|
Initiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe hidradenitis suppurativa (HS) in Q2 2025
Continued progress in the Phase 2 TibuSURE clinical study evaluating tibulizumab in adults with systemic sclerosis (SSc)
Appointed new executive and board leadership to support ongoing growth and development
Reported $154.5 million in cash and cash equivalents as of June 30, 2025; expected to fund planned operations through 2027
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company dedicated to developing novel dual-pathway antibodies for autoimmune and inflammatory diseases with unmet needs, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates.
“The second quarter of 2025 marked continued progress across our clinical programs and organizational goals,” said Robert Lisicki, Ch...
|
|
|
|
|
01.07.25 - 12:36
|
Zura Bio Announces Chief Financial Officer Transition (Business Wire)
|
|
|
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transition.
Mr. Badial joined Zura Bio in March 2023, at the time of its business combination with JATT Acquisition Corporation. He led the development of Zura Bio's internal financial and operational systems, contributed to shaping its financial strategy, and participated in capital-raising efforts that supported the company's early growth.
Mr. Hyllengren brings over 20 years of financial leadership experience in the life sciences and biotechnology sectors. He most recently served as Chief Operatin...
|
|
|
|
|
08.05.25 - 12:36
|
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire)
|
|
|
Advanced the Phase 2 TibuSURE clinical trial evaluating tibulizumab in adults with systemic sclerosis (SSc)
Continued preparations for the planned Phase 2 trial evaluating tibulizumab in adults with hidradenitis suppurativa (HS), expected to initiate in Q2 2025
Strengthened the team with a strategic appointment to support clinical execution and organizational growth
$170.6 million in cash and cash equivalents with cash runway anticipated through 2027
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates.
“The first quarter of 2025 reflected steady progress across our clinical and operational priorities,” said Robert Lisicki, Chief Executive Officer of Zura Bio. “We continued adva...
|
|
|
25.03.25 - 11:36
|
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates (Business Wire)
|
|
|
Achieved key milestones in 2024 that enhanced our leadership team, strengthened our financial position, and progressed our clinical pipeline
Initiated the Phase 2 TibuSURE trial in adults with systemic sclerosis (SSc)
Completed a $112.5 million private placement financing in April 2024, contributing to a total of $176.5 million in cash and cash equivalents, as of December 31, 2024
Cash runway anticipated through 2027, supporting operations and funding anticipated tibulizumab data readouts in SSc and hidradenitis suppurativa (HS)
HENDERSON, Nev.--(BUSINESS WIRE)--$ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates.
“In 2024, we reached key milestones that reinforced our financial foundation, expanded our leadership team, and advanced our clinical pipeline, highlig...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
